These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27317952)

  • 21. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
    Nagayama S; Hasegawa S; Hida K; Kawada K; Hatano E; Nakamura K; Seo S; Taura K; Yasuchika K; Matsuo T; Zaima M; Kanazawa A; Terajima H; Tada M; Adachi Y; Nishitai R; Manaka D; Yoshimura T; Doi K; Horimatsu T; Mitsuyoshi A; Yoshimura K; Niimi M; Matsumoto S; Sakai Y; Uemoto S
    Int J Clin Oncol; 2017 Apr; 22(2):316-323. PubMed ID: 27752787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topics related to neoadjuvant chemotherapy for resectable liver metastases from colorectal cancer.
    Ke S; Zhan S; Zhu H; Yan D
    J BUON; 2018; 23(2):296-301. PubMed ID: 29745068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.
    Knowles B; Welsh FK; Chandrakumaran K; John TG; Rees M
    HPB (Oxford); 2012 May; 14(5):298-309. PubMed ID: 22487067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001).
    Katayose Y; Yamamoto K; Nakagawal K; Takemura S; Takahashi M; Nakamura R; Shimamura H; Rikiyama T; Egawa S; Yoshda H; Motoi F; Naitoh T; Unno M
    Hepatogastroenterology; 2015; 62(138):303-8. PubMed ID: 25916054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
    Hebbar M; Pruvot FR; Romano O; Triboulet JP; de Gramont A
    Cancer Treat Rev; 2009 Dec; 35(8):668-75. PubMed ID: 19733977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
    Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative chemotherapy for resectable colorectal liver metastases: where now?
    Jones RP; Malik HZ; Fenwick SW; Poston GJ
    Eur J Surg Oncol; 2013 Aug; 39(8):807-11. PubMed ID: 23726258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer.
    Araujo R; Gonen M; Allen P; Blumgart L; DeMatteo R; Fong Y; Kemeny N; Jarnagin W; D'Angelica M
    Ann Surg Oncol; 2013 Dec; 20(13):4312-21. PubMed ID: 23897009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical risk scores in the current era of neoadjuvant chemotherapy for colorectal liver metastases.
    Kumar R; Dennison AR; Robertson V; Jones MJ; Neal CP; Garcea G
    ANZ J Surg; 2018 Jan; 88(1-2):E16-E20. PubMed ID: 27621179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases.
    Oh SY; Kim DY; Kim YB; Suh KW
    J Surg Res; 2013 Jun; 182(2):257-63. PubMed ID: 23253254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
    Ihnát P; Vávra P; Zonča P
    World J Gastroenterol; 2015 Jun; 21(22):7014-21. PubMed ID: 26078580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection.
    Lim E; Wiggans MG; Shahtahmassebi G; Aroori S; Bowles MJ; Briggs CD; Stell DA
    HPB (Oxford); 2016 Jul; 18(7):586-92. PubMed ID: 27346139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CALy Prognostic Score (CEA, ALP, Lymphocyte Count) as a predictor of survival after hepatectomy for liver-only colorectal metastases.
    Neofytou K; Giakoustidis A; Mudan S
    J BUON; 2015; 20(3):746-55. PubMed ID: 26214626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
    House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
    Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
    J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
    Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
    J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.